Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study

E. L. Kramer, S. J. DeNardo, L. Liebes, L. A. Kroger, M. E. Noz, H. Mizrachi, Q. A. Salako, P. Furmanski, S. D. Glenn, Gerald L Denardo, R. Ceriani

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5% ± 19.3% injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56%ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.

Original languageEnglish (US)
Pages (from-to)1067-1074
Number of pages8
JournalJournal of Nuclear Medicine
Volume34
Issue number7
StatePublished - 1993
Externally publishedYes

Fingerprint

Pentetic Acid
Indium
Monoclonal Antibodies
Breast Neoplasms
Antibodies
Pharmacokinetics
Radiation
Neoplasms
Mucins
Epitopes
Hypersensitivity
Breast
Urine
Serum
benzyl-DTPA
Therapeutics

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Kramer, E. L., DeNardo, S. J., Liebes, L., Kroger, L. A., Noz, M. E., Mizrachi, H., ... Ceriani, R. (1993). Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study. Journal of Nuclear Medicine, 34(7), 1067-1074.

Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody : Phase I study. / Kramer, E. L.; DeNardo, S. J.; Liebes, L.; Kroger, L. A.; Noz, M. E.; Mizrachi, H.; Salako, Q. A.; Furmanski, P.; Glenn, S. D.; Denardo, Gerald L; Ceriani, R.

In: Journal of Nuclear Medicine, Vol. 34, No. 7, 1993, p. 1067-1074.

Research output: Contribution to journalArticle

Kramer, EL, DeNardo, SJ, Liebes, L, Kroger, LA, Noz, ME, Mizrachi, H, Salako, QA, Furmanski, P, Glenn, SD, Denardo, GL & Ceriani, R 1993, 'Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study', Journal of Nuclear Medicine, vol. 34, no. 7, pp. 1067-1074.
Kramer, E. L. ; DeNardo, S. J. ; Liebes, L. ; Kroger, L. A. ; Noz, M. E. ; Mizrachi, H. ; Salako, Q. A. ; Furmanski, P. ; Glenn, S. D. ; Denardo, Gerald L ; Ceriani, R. / Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody : Phase I study. In: Journal of Nuclear Medicine. 1993 ; Vol. 34, No. 7. pp. 1067-1074.
@article{da723d4f828f476e9d4691eb6a7e0682,
title = "Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study",
abstract = "Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5{\%} ± 19.3{\%} injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56{\%}ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.",
author = "Kramer, {E. L.} and DeNardo, {S. J.} and L. Liebes and Kroger, {L. A.} and Noz, {M. E.} and H. Mizrachi and Salako, {Q. A.} and P. Furmanski and Glenn, {S. D.} and Denardo, {Gerald L} and R. Ceriani",
year = "1993",
language = "English (US)",
volume = "34",
pages = "1067--1074",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Radioimmunolocalization of metastatic breast carcinoma using indium-111- methyl benzyl DTPA BrE-3 monoclonal antibody

T2 - Phase I study

AU - Kramer, E. L.

AU - DeNardo, S. J.

AU - Liebes, L.

AU - Kroger, L. A.

AU - Noz, M. E.

AU - Mizrachi, H.

AU - Salako, Q. A.

AU - Furmanski, P.

AU - Glenn, S. D.

AU - Denardo, Gerald L

AU - Ceriani, R.

PY - 1993

Y1 - 1993

N2 - Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5% ± 19.3% injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56%ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.

AB - Pharmacokinetics of radiolabeled BrE-3 monoclonal antibody (Mab), reactive against a breast mucin epitope, were assessed in 15 patients with advanced breast cancer. Patients received 5 mCi (185 MBq) of 111In-methyl benzyl isothiocyanate DTPA (MX-DTPA) conjugated BrE-3 Mab intravenously with total antibody doses of 10, 50 or 100 mg. Serial quantitative imaging, blood and urine clearance were obtained to measure pharmacokinetics, assess tumor localization and estimate radiation dose. Organ function was followed to determine toxicity. Mild allergic reactions occurred in four patients. Eighty-six percent of 70 known lesions and 5 unsuspected lesions were detected by antibody imaging. Biexponential modeling of radiolabeled antibody in serum showed a T( 1/2 (α)) = 9.5 ± 2.7 hr and T( 1/2 (β)) = 56 ± 25.4 hr. Total urinary excretion averaged 35.5% ± 19.3% injected dose (ID) by Day 8. Quantitative imaging showed that 0.02-2.56%ID localized in tumors. Extrapolating dosimetry from 111In-MX-DTPA-BrE-3 to 90Y-MX-DTPA-BrE-3, we estimate therapeutic radiation doses could be delivered to some tumors with tolerable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0027176884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027176884&partnerID=8YFLogxK

M3 - Article

C2 - 8315480

AN - SCOPUS:0027176884

VL - 34

SP - 1067

EP - 1074

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -